Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 141 clinical trials
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

advanced or metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer and HER2-positive advanced breast cancer with liver metastasis.

taxane
epidermal growth factor receptor
advanced breast cancer
lapatinib
breast cancer
  • 135 views
  • 10 Mar, 2022
  • 67 locations
Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer (PHC-BC)

epidermal growth factor receptor-2 (HER-2) positive primary breast cancer.

trastuzumab
her1
growth factor
core needle biopsy
her-2
  • 0 views
  • 05 Mar, 2022
  • 1 location
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

pharmacokinetics of BPI-1178 in subjects with advanced solid tumor, as well as the subjects with advanced hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer.

solid tumour
epidermal growth factor receptor
fulvestrant
breast cancer
international normalized ratio
  • 0 views
  • 08 Aug, 2021
  • 1 location
Combined Immunotherapies in Metastatic ER+ Breast Cancer

Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for

epidermal growth factor receptor
growth factor
EGFR
palbociclib
letrozole
  • 0 views
  • 11 Jul, 2021
  • 5 locations
A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

dose(RP2D) of XZP-3287 and its efficacy and safety in hormone receptor(HR) positive, human epidermal growth factor receptor 2(HER2) negative advanced breast cancer.

  • 0 views
  • 25 Jan, 2021
  • 1 location
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

HER2 (human epidermal growth factor receptor 2) positive breast cancer.

  • 0 views
  • 01 May, 2022
  • 1 location
A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

. Eligible patients include those with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-positive breast cancer.

  • 0 views
  • 10 May, 2022
  • 13 locations
A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations (PINNACLE)

epidermal growth factor receptor 2 (HER2) exon 20 mutations when treated with poziotinib versus docetaxel.

  • 0 views
  • 23 May, 2022
  • 1 location
Afatinib in Advanced Refractory Urothelial Cancer

chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause

absolute neutrophil count
systemic chemotherapy
carcinoma
metastatic urothelial carcinoma
chemotherapy regimen
  • 29 views
  • 07 Oct, 2021
  • 5 locations
Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions

Various driver gene mutations have been identified in lung cancer. Among them, human epidermal growth factor 2 (HER2) was identified in approximately 2% of non-small-cell lung cancers. Pyrotinib

  • 0 views
  • 03 Feb, 2021
  • 1 location